Curated news and analysis on clinical trials, drug approvals, and medical research.
Two studies found cardiac MRI-derived biomarkers may improve heart failure risk assessment. Epicardial adipose tissue index was linked to HFpEF risk, while imaging-derived SvO2 predicted hospitalization and death.
Psyence Biomedical dosed the first patient in a Phase IIb study of NPX-5 in Adjustment Disorder among cancer patients receiving palliative care. The randomized, double-blind trial is running across five Australian sites.
Biotech innovation is reshaping nutricosmetics and haircare as products move beyond cosmetic claims toward biological mechanisms and preventive wellness. Haircare formulations are using lab-engineered proteins, fermentation-derived actives and peptide technology.
The iPSC-derived NK cells pipeline includes 12+ active players and 15+ drugs in development. FT522 is in Phase I, while CNTY-101 and NCR300 are among other programs in the clinic.
A longitudinal study of 460,000 teenagers found adolescent cannabis use was linked to higher risks of later bipolar, psychotic, anxiety and depression diagnoses. Separate research and expert guidance say THC effects, especially long term, still need more study.
Yale Cancer Center experts presented research at the 2026 AACR Annual Meeting in San Diego, including patient-centered trials, pathology methods and head and neck cancer studies. The meeting also included a plenary presentation, a pathology award and an AACR Trailblazer Cancer Research Grant.
Early-phase trials are evaluating cellular therapies to improve transplant tolerance in kidney care. Investigators are testing whether some recipients can safely reduce immunosuppression to a single agent.
A federal appeals court affirmed a ruling finding no infringement of two Korlym-related patents by Teva's proposed generic. The decision removes a major legal barrier for generic competition.
A meta-analysis in BMC Ophthalmology found distinct gut microbiome compositional and functional alterations in diabetic retinopathy. The review identified depleted SCFA-producing bacteria, enriched pro-inflammatory bacteria, and dysregulated metabolic pathways.
Gravity Rail launched with a $2.75 million seed investment led by Redesign Health. The no-code, model-agnostic platform lets healthcare teams build AI engagement workflows and reported early gains in referral appointments and trial recruitment.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
The Trump administration moved to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. The change is expected to ease research restrictions but will not immediately legalize marijuana.
Danaher agreed to acquire Masimo for $9.9 billion, paying $180 per share to expand its diagnostics portfolio into blood oxygen monitoring and patient monitoring devices. Danaher also launched nearly €3 billion in senior notes to help fund the deal, which is expected to close by the second half of 2026.
The University of Houston and DHR Health broke ground on a 64,000-square-foot medical research and education center in McAllen. Backed by a $15 million state appropriation, the project will expand physician training, research and health education in the Rio Grande Valley.
The FDA reversed course and said it would review Moderna’s application for a new mRNA-based flu vaccine. The move followed growing concern about federal vaccine policy and came after HHS canceled nearly $500 million in mRNA vaccine contracts.
Retail pharmacy chains that expanded into clinical trials after COVID have since slowed or pulled back. CVS said it would exit by the end of 2024, Walmart shut its health clinics in 2024, and Walgreens has not commented formally on its business status.
A study in stage 3 dMMR colon cancer found that atezolizumab plus chemotherapy after surgery cut recurrence and death risk by 50%. The trial enrolled 712 patients and the regimen is now included in treatment guidelines.
AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.
UK Research and Innovation has announced major changes to grant funding, with pauses and cuts affecting medical, biological and physical research. The uncertainty has raised concern over curiosity-driven research, staffing and the system’s tolerance for failure.
The FDA’s publication of complete response letters has tightened company disclosure around drug rejections and exposed common approval hurdles. Analyses of the letters point to frequent facilities and product quality deficiencies and delays averaging more than 2.5 years to final approval.
